|Antibody Name:||Fd138-80 (IgG SGII | k SGV)|
Co, M.S., Deschamps, M., Whitley, R.J. and Queen, C.
"Humanized antibodies for antiviral therapy."
Proc. Natl. Acad. Sci. USA (1991) 88: 2869-2873.
(See also mAb Fd79 in this reference).
|Acceptor Antibody:||Human IgG1 | k|
|Antigen:||Herpes simplex virus (HSV) gD glycoprotein|
|Laboratory:||Protein Design Labs, CA; Univ. Alabama, AL|
|Design:||As for Anti-Tac.|
|Frameworks:||VH human EU | VL human EU|
|CDRs:||All 6 from VH and VL, Kabat Definition.|
VH G27Y S30T M48F R66K V67A | VL Y36H (structural model suggests contacts with CDRs)
VH V37M | VL Y87F (model suggests contact with F98:L adjacent to CDR)
VH F89V G94R E103W Y104G N105Q G107T | VL M48I I63T (atypical amino acids, backmutations consistent with human consensus)
|Binding:||The humanised mAb's affinity is "comparable" to the mouse mAb as assessed by competition binding.|
|Expression:||Sp2/0 mouse myeloma cells|
|Comment:||Assays showed the humanised mAb had neutralising activity for HSV-1|
|José Saldanha © 1997-8. Birkbeck College, London WC1E 7HX.|